1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,750 | 6,000 | 01.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | LEADS BIOLABS CO., LTD.: Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition | 5 | GlobeNewswire (USA) | ||
| Mo | LEADS BIOLABS-B 's LBL-024 Granted Orphan Drug Designation in Japan | 1 | AASTOCKS | ||
| Mo | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) GRANTED ORPHAN DRUG DESIGNATION IN JAPAN | 1 | HKEx | ||
| NANJING LEADS BIOLABS Aktie jetzt für 0€ handeln | |||||
| 23.09. | LEADS BIOLABS-B (09887): 2026 INTERIM REPORT | 1 | HKEx | ||
| 21.09. | LEADS BIOLABS CO., LTD.: Leads Biolabs' Pivotal Phase IIb Study of Opamtistomig (LBL-024) in Advanced EP-NEC Selected as ESMO 2026 Late-Breaking Abstract; Three Studies Selected for Proffered Paper Presentations | 6 | GlobeNewswire (USA) | ||
| 21.09. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT PIVOTAL REGISTRATIONAL PHASE IIB STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) MONOTHERAPY ... | 1 | HKEx | ||
| 17.09. | M Stanley Upgrades LEADS BIOLABS-B to "Overweight", Raises TP to HKD93 | 2 | AASTOCKS | ||
| 14.09. | LEADS BIOLABS CO., LTD.: WCLC 2026 | Leads Biolabs' Opamtistomig (LBL-024) Oral Presentation Demonstrates Robust Response and PFS Benefits in First-Line NSCLC | 3 | GlobeNewswire (USA) | ||
| 14.09. | LEADS BIOLABS-B 'Vilizimab' Phase II NSCLC Combination Therapy Study Reports 71% ORR | 1 | AASTOCKS | ||
| 14.09. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT UPDATED DATA FROM PHASE II CLINICAL STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) IN ... | - | HKEx | ||
| 04.09. | CLSA: China Biotech Fundamentals Remain Solid; Top Picks BEONE MEDICINES, INNOVENT BIO and LEADS BIOLABS-B | 5 | AASTOCKS | ||
| 03.09. | M Stanley Raises LEADS BIOLABS-B TP to HKD85, Rated Equalweight | 2 | AASTOCKS | ||
| 02.09. | CLSA Raises LEADS BIOLABS-B TP to HKD116.9, LBL-024 Data to Be Released Soon | 1 | AASTOCKS | ||
| 31.08. | LEADS BIOLABS-B (09887): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 2 | HKEx | ||
| 25.08. | LEADS BIOLABS CO., LTD.: Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage | 2 | GlobeNewswire (USA) | ||
| 25.08. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) PHASE II CLINICAL STUDY FOR FIRST-LINE TREATMENT ... | 1 | HKEx | ||
| 21.08. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) NEW DRUG APPLICATION ACCEPTED FOR REVIEW BY NMPA | 1 | HKEx | ||
| 20.08. | LEADS BIOLABS CO., LTD.: Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow-Up Shows Continued Efficacy Improvement | 1 | GlobeNewswire (USA) | ||
| 20.08. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) PHASE II CLINICAL STUDY ABSTRACT FOR FIRST-LINE ... | 1 | HKEx | ||
| 20.08. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT OBLENIO EXERCISED OPTION TO RETAIN ITS LICENSE FOR LBL-051 | 1 | HKEx |
1 2 3 4 Weiter >>
62 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRUCTURE THERAPEUTICS | 28,980 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel | SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,680 | -0,06 % | Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft | DJ Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft
Von Elias Schisgall
DOW JONES--Astrazeneca investiert im Rahmen einer erweiterten Partnerschaft 2 Milliarden... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 75,22 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| QIAGEN | 38,190 | -1,37 % | DAX-Gewinner im September: Die fünf Top-Aktien im DAX - Diese 5 Aktien ließen die Konkurrenz hinter sich | © Foto: Rafael Henrique - picture allianceDer September bringt Bewegung in den DAX. Auf 30-Tage-Sicht konnten vor allem Qiagen, MTU Aero Engines und die Commerzbank überzeugen. Ein Überblick über die... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 4,740 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6- month interim analysis and FDA feedback on the BLA... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 11,260 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk | In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases, normalized... ► Artikel lesen | |
| MBX BIOSCIENCES | 56,55 | 0,00 % | MBX Biosciences auf dem Stifel Cardiometabolic Forum: Pipeline setzt auf optimierte Dosierung | ||
| PRAXIS PRECISION MEDICINES | 287,06 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,070 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program | Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated... ► Artikel lesen | |
| DYNE THERAPEUTICS | 15,810 | -0,06 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen | |
| MODERNA | 168,82 | +0,40 % | Nur noch 4 Spritzen im Jahr?: Dieser Novo-Deal lässt eine kleine Pharma-Aktie um bis zu 161 % explodieren | © Foto: Steffen Trumpf - dpaNovo Nordisk sichert sich exklusiv eine Technologie, die Adipositas- und Diabetesmedikamente künftig deutlich seltener nötig machen könnte. Für Nanexa wird der Deal zum Börsenfeuerwerk... ► Artikel lesen | |
| PARABILIS MEDICINES | 30,440 | 0,00 % | Parabilis Medicines, Inc.: Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates | Advanced zolucatetide across multiple Wnt/ß-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors Announced strategic research collaboration with... ► Artikel lesen | |
| TANGO THERAPEUTICS | 24,450 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 110,06 | -0,05 % | B.Riley reiterates Kymera Therapeutics stock rating on new trial data | ||
| RELAY THERAPEUTICS | 18,480 | -0,05 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen |
Das Unternehmen NANJING LEADS BIOLABS CO LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 5,650 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANJING LEADS BIOLABS CO LTD finden Sie auf Wallstreet Online.